700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Review Article Open Access
There are theoretical and practical constraints associated with using molecular biomarkers in the diagnosis of Alzheimer’s disease (AD) during preclinical stages when patients are asymptomatic. Event-related potentials (ERPs) provide an affordable measure of neurological functioning and have been used extensively to measure the onset and progression of cognitive decline in AD. However, the traditional paradigms used to elicit ERPs in the context of AD are influenced by unwanted factors such as ageing, cultural background and education, as well as other neuropsychiatric conditions and comorbidities. We propose that a revision of the task domain is necessary to increase the sensitivity and specificity of ERP measurements. Performance on the short-term memory binding task (STMBT) is highly specific to AD and mirrors the trajectory of neurological pathology in preclinical samples. Theorydriven cognitive assessments, electrophysiology and the emergence of mobile neuroimaging systems may serve as a fundamental combination to overcome the challenges of diagnosing preclinical AD.
Alzheimer&rsquo,s disease, EEG, ERP, Preclinical diagnosis, Mild cognitive impairment, Subjective cognitive decline, Alzheimer?s disease, EEG, ERP, Preclinical diagnosis, Mild cognitive impairment, Subjective cognitive decline